阿立哌唑与氟哌啶醇治疗精神分裂症对照研究  

Comparison study of aripiprazole and haloperidol in treatment of schizophrenia

作　　者：周卉[1] 李朝[1] 诸索宇[1] 凌政[1] 王慧芳[1] 王飙[1] 江开达[1] 

机构地区：[1]上海市精神卫生中心,200030

出　　处：《临床精神医学杂志》2007年第6期411-412,共2页Journal of Clinical Psychiatry

摘　　要：目的:评价阿立哌唑与氟哌啶醇治疗精神分裂症的疗效及安全性。方法:阿立哌唑组50例,氟哌啶醇组48例,以阳性与阴性症状量表(PANSS)、临床疗效总评量表疾病严重程度(CGI-SI)、治疗中出现的症状量表(TESS)、锥体外系反应量表(RSESE)评定疗效及不良反应。疗程6周。结果:两组疗效相仿。阿立哌唑组PANSS阴性症状因子减分在治疗后4及6周显著优于氟哌啶醇组。阿立哌唑组不良反应显著较少。结论:阿立哌唑是一有效安全的抗精神病药。Objective： To compare the efficacy and safety of aripiprazole and haloperidol in treatment of schizophrenia. Method： Antipsychotic efficacy was assessed by positive and negative symptom scale （PANSS） and clinical global impressions-severity of illness rating scale （ CGI-SI）, antipsychotic side effect was assessed by treatment emergent symptom scale （TESS） and rating scale for extrapyrarnidal side effects （RSESE） in 50 patients treated by aripiprazole （aripiprazole group） and 48 patients treated by haloperidol （haloperidol group） for six weeks. Results： The efficacy was similar in two groups. The reduction of total negative score in patients of aripiprazole group was significantly higher than that in haloperidol group after 4 and 6 weeks. Patients in aripiprazole group had significantly less side effects. Conclusion： Aripiprazole is an effective and safe antipsychotic.

关 键 词：阿立哌唑 氟哌啶醇 精神分裂症 

分 类 号：R749.053[医药卫生—神经病学与精神病学]